The pharmaceutical industry in our country is showing an accelerated development trend. According to data from the Ministry of Industry and Information Technology, in September of this year, the growth rate of added value in the national pharmaceutical industry reached 10.5%, accounting for 3.7% of the total industry, and the market size of innovative drugs exceeded 100 billion yuan. At the 2024 China Pharmaceutical Industry Development Conference held recently, Minister of Industry and Information Technology Jin Zhuanglong stated that China's pharmaceutical industry has significantly enhanced its innovation capabilities, with the number of new drugs under development ranking second in the world. In 2024, 37 innovative drugs and 51 innovative medical devices will be approved for market, and cutting-edge fields such as new antibodies, nucleic acid vaccines, cell and gene therapy drugs will be among the top in the world. International cooperation continues to deepen. In 2024, the total volume of foreign technology licensing transactions of Chinese pharmaceutical enterprises will exceed 34 billion dollars. A number of high-quality traditional Chinese patent medicines and simple preparations have gone global, and 503 registration approvals have been obtained in 47 countries or regions. All links in the pharmaceutical innovation chain are showing a good development trend. Zeng Yixin, Deputy Secretary of the Party Group and Deputy Director of the National Health Commission, introduced that China's total R&D resources and R&D capabilities have reached a high level, and the R&D capabilities and levels of innovative drugs have also significantly improved, continuously gaining recognition from the international market. Our country's share of new drug research and development worldwide is close to 30%, which is a huge progress. Not only has the number of drugs increased, but the innovation level and clinical value of newly developed drugs are also increasingly recognized internationally Chen Kaixian, academician of the CAS Member and researcher of the Chinese Academy of Sciences Shanghai Institute of Materia Medica, said. The report "Outstanding Progress in Industrial Upgrading and Key Areas for Future Development of Industrial Technology in the Pharmaceutical Industry during the 14th Five Year Plan Period" released at the meeting shows that since the 14th Five Year Plan period, a total of 113 domestically produced innovative drugs have been approved for market, which is 2.8 times the number of new drugs approved during the 13th Five Year Plan period, and the market size has reached 100 billion yuan. High end medical devices are accelerating innovation breakthroughs, with a total of 165 innovative medical devices developed by Chinese companies approved for listing. During the 14th Five Year Plan period, the industrialization capacity of biopharmaceuticals has significantly increased. Key technologies such as large-scale cell culture and purification are approaching the international advanced level, and a number of high-level factories have been built in the fields of antibody drugs, gene therapy and cell therapy drugs, new vaccines, peptide drugs, etc. The research and development level of complex formulations has rapidly improved. Increasing the variety of products on the market, timely filling the domestic gap, significantly reducing the disease burden of patients, and better meeting their medication needs. In addition, the intelligent manufacturing level system of the entire industry has been improved. The application of digital technologies such as artificial intelligence, big data, and cloud computing in the pharmaceutical industry is constantly expanding, and the integration of information technology and the pharmaceutical industry is becoming deeper, marking a new stage of intelligent manufacturing for China's pharmaceutical industry. Jin Zhuanglong stated that he will increase efforts in technological innovation in the pharmaceutical industry. Improve the collaborative research and development system between industry, academia, research and medical institutions, coordinate and strengthen the supply chain, and accelerate the industrialization process of major innovative products. Consolidate and enhance competitive advantages, promote the transformation of cutting-edge technologies, and actively develop new quality productivity. At the same time, promote the transformation and upgrading of the pharmaceutical industry. Adhere to high-end, intelligent, and green development, cultivate world-class pharmaceutical enterprises, and build a high-end pharmaceutical industry cluster. Zeng Yixin believes that in order to give full play to the supporting and driving role of technological innovation in the innovative development of the pharmaceutical industry, efforts should be made to comprehensively improve the output of major original achievements, breakthroughs in key core technologies, and the construction of talent systems and research and development platforms. Focusing on the integration of innovation chain and policy chain, strengthening the coordination of policies and mechanisms in scientific and technological innovation and medical service system, medical insurance payment mechanism, drug supervision, drug system, etc., promoting the realization of a policy system that supports the entire innovation chain, jointly promoting the development of new quality production capacity in the field of health, and better supporting the goal of building a healthy China and a strong science and technology country. Chen Kaixian believes that solving problems such as homogenization in the biopharmaceutical industry not only requires the government to further strengthen policy guidance and optimize industrial layout; Enterprises should also strengthen the construction of original innovation capabilities, improve their level of independent innovation, pay attention to market demand research, and develop distinctive products; Capital should have a long-term vision, investing early, small, hard technology, and long-term, and provide more support for original pharmaceutical research and development. It is understood that the Ministry of Industry and Information Technology will enhance its pharmaceutical production and supply capabilities. Improve the national pharmaceutical reserve system, strengthen the research and production of clinically scarce drugs, children's drugs, and rare disease drugs, and effectively meet the needs of public health emergencies and medication for the public. At the same time, further expand the opening and cooperation of the pharmaceutical industry. Create a market-oriented, rule of law, and international first-class business environment to attract global innovation factors to gather. Adhere to the equal emphasis on traditional Chinese and Western medicine, promote the inheritance, innovation and development of traditional Chinese medicine, and high-quality "going global". (New Society)